Catalyst
Slingshot members are tracking this event:
Gilead (GILD) Plans to Submit Marketing Authorization Application (MAA) to European Commission for Bictegravir (B/F/TAF) Single Tablet HIV-1 Infection Regimen in Q3 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Occurred Source:
http://www.gilead.com/news/press-releases/2017/7/european-medicines-agency-validates-gileads-marketing-application-for-fixeddose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Marketing Authorization Application, Maa, European Commission, Bictegravir, B/f/taf, Single Tablet, Hiv-1 Infection, Emtricitabine, Tenofovir Alafenamide
